| Dr Justin Belanger, DC | |
|
1084 Broad St, Central Falls, RI 02863-1516 | |
| (401) 365-1212 | |
| (401) 365-1214 |
| Full Name | Dr Justin Belanger |
|---|---|
| Gender | Male |
| Speciality | Chiropractic |
| Experience | 6 Years |
| Location | 1084 Broad St, Central Falls, Rhode Island |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003393901 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | DCP00666 (Rhode Island) | Primary |
| Provider Name | Decrescenzo Chiropractic, Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1013036326 PECOS PAC ID: 5698800340 Enrollment ID: O20100319000148 |
News Archive
The U.S. obesity prevalence increased from 13 percent to 32 percent between the 1960s and 2004, according to researchers at the Johns Hopkins Bloomberg School of Public Health Center for Human Nutrition.
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing non-systemic, orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners. In conjunction with the MPM investment, managing director Ashley Dombkowski, Ph.D., will join Alnara's board of directors.
GOP presidential hopeful Herman Cain is scheduled today to give a Capitol Hill speech that is expected to focus on his health care policies and positions. Also in the news, a Washington Post fact-check examines claims by Mitt Romney, another GOP candidate, regarding health care subsidies.
ReVision Optics, a leading company in the research, development and manufacture of implantable medical devices designed to assist patients that need reading glasses, announced today that it has completed enrollment and initial follow up in Phase I of its US clinical trial and has filed for expansion. The clinical trial is for the study of the PresbyLens, recently renamed Vue+, for the improvement of near vision in patients with presbyopia, the age-related loss of near vision.
› Verified 7 days ago
| Provider Name | Belanger Chiropractic Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1306887237 PECOS PAC ID: 6406259886 Enrollment ID: O20210722001598 |
News Archive
The U.S. obesity prevalence increased from 13 percent to 32 percent between the 1960s and 2004, according to researchers at the Johns Hopkins Bloomberg School of Public Health Center for Human Nutrition.
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing non-systemic, orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners. In conjunction with the MPM investment, managing director Ashley Dombkowski, Ph.D., will join Alnara's board of directors.
GOP presidential hopeful Herman Cain is scheduled today to give a Capitol Hill speech that is expected to focus on his health care policies and positions. Also in the news, a Washington Post fact-check examines claims by Mitt Romney, another GOP candidate, regarding health care subsidies.
ReVision Optics, a leading company in the research, development and manufacture of implantable medical devices designed to assist patients that need reading glasses, announced today that it has completed enrollment and initial follow up in Phase I of its US clinical trial and has filed for expansion. The clinical trial is for the study of the PresbyLens, recently renamed Vue+, for the improvement of near vision in patients with presbyopia, the age-related loss of near vision.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Justin Belanger, DC 160 Taunton Ave, East Providence, RI 02914-4531 Ph: (401) 270-8865 | Dr Justin Belanger, DC 1084 Broad St, Central Falls, RI 02863-1516 Ph: (401) 365-1212 |
News Archive
The U.S. obesity prevalence increased from 13 percent to 32 percent between the 1960s and 2004, according to researchers at the Johns Hopkins Bloomberg School of Public Health Center for Human Nutrition.
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing non-systemic, orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners. In conjunction with the MPM investment, managing director Ashley Dombkowski, Ph.D., will join Alnara's board of directors.
GOP presidential hopeful Herman Cain is scheduled today to give a Capitol Hill speech that is expected to focus on his health care policies and positions. Also in the news, a Washington Post fact-check examines claims by Mitt Romney, another GOP candidate, regarding health care subsidies.
ReVision Optics, a leading company in the research, development and manufacture of implantable medical devices designed to assist patients that need reading glasses, announced today that it has completed enrollment and initial follow up in Phase I of its US clinical trial and has filed for expansion. The clinical trial is for the study of the PresbyLens, recently renamed Vue+, for the improvement of near vision in patients with presbyopia, the age-related loss of near vision.
› Verified 7 days ago